MYCN and neoplasm: NEPC tumours have been characterized with (1) gains in MYCN and AURKA [5]; (2) overexpression of PEG10 [24], HP1α [25], N-Myc [26, 27], SOX2 [28], and SOX11 [18]; (3) down-regulation of PHF8, KDM3A [29, 30], REST [31], and SPEDF [32]; and lastly (4) disease dependency on GPX4 [33].